| Name | JIB-04 |
| Description | JIB-04 (NSC 693627) is a pan-selective Jumonji histone demethylase inhibitor. |
| Cell Research | For cell viability assays, cells are plated at 1500-3000 cells/well in 96 well plates and treated the next day with increasing doses of compound over 4 days and their viability assessed by standard MTS assays using Promega’s Cell Titer or Cell Titer-Glo reagents according to the manufacturer’s protocols. Absorbance at 490 nm and 650 nm or luminescence is measured by a Spectra Max or a FlouroStar Omega plate reader. Data are normalized to the untreated controls (100% viability). Each cell line is tested in 2-5 independent assays, each containing 4-8 replicates. IC50 values are calculated using DIVISA, a high-throughput software, developed in hous, for storing and analyzing drug sensitivity assays. Dose-response curves are plotted using a non-linear regression model and IC50s are determined from the fitted curves. The average IC50 derived from 2-5 independent assays, each containing 4-8 replicates is reported. (Only for Reference) |
| In vitro | In the H358 and A549 mouse xenograft models, JIB-04 inhibits the activity of Jumonji domain-containing histone demethylases, thereby suppressing tumor cell growth. |
| In vivo | In lung and prostate cancer cell lines (IC50=10 nM), JIB-04 downregulates proliferation genes and inhibits cell growth. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.48 mM), Sonication is recommended.
DMSO : 36.43 mg/mL (117.99 mM), Sonication is recommended.
|
| Keywords | NSC-693627 | NSC693627 | JMJD2E | JMJD2D | JMJD2B | JMJD2A | JIB-04 | JIB04 | JARID1A | Inhibitor | inhibit | HistoneMethyltransferase | HistoneDemethylase | Histone Methyltransferase | Histone Demethylase | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Reprogramming Compound Library | Histone Modification Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Epigenetics Compound Library | Chromatin Modification Compound Library | Inhibitor Library | NO PAINS Compound Library | Stem Cell Differentiation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
United States
